A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.

Janssen (J&J Innovative Medicine)

Status: Completed

Conditions: Psoriasis

Treatments: Other: Clinical profile of patients; Other: Patient Preferences about treatment; Other: Quality of Life

Study type: Observational

Funder types: Industry

Identifiers

NCT01262534

CR017545

CNTO1275PSO4013 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to assess the clinical profile of patients with moderate to severe psoriasis in Spain. The primary objective is to analyze the clinical profile of patients with moderate to severe psoriasis, as defined by a set of conditions (obesity, hypertension, diabetes, abnormal amounts of lipids in the blood, cardiovascular disease, etc.) and its correlation to the patients' quality of life. The secondary objectives are to describe the demographic characteristics and habits of the patient, to evaluate the clinical characteristics of the disease, and to describe the diagnostic and therapeutic procedures being used in standard clinical practice and the patients' expectations for these therapies.

Full description

This is an epidemiological, non-interventional, multi-centre, cross-sectional, retrospective, observational study to assess the clinical profile of patients with moderate to severe psoriasis in Spain. The data for each patient will be recorded only once, in one visit. During this visit the specialist will ask the patient a series of questions to describe the existence or absence of a number of conditions and their associated treatments, to record the characteristics of psoriasis experienced by the patient and the type of associated treatment. Not applicable

Enrollment: 1,042 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient over 18 years of age
• Diagnosed with psoriasis at least 6 months before the visit
• Diagnosed with moderate to severe psoriasis
• Who have been treated or not for moderate to severe psoriasis
• For whom the medical history dating back at least 6 months can be accessed
• the patient's legal representative has signed informed consent, stating that the patient understands the study purpose and requirements and grants the patient consent to participate in the study

Exclusion criteria

• Patient diagnosed with mild psoriasis according to the dermatologist or with a skin disease other than psoriasis
• With any type of difficulty understanding the questions in the DLQI, SF-36 and PBI questionnaires
• Who and/or whose legal representative refuses to grant written, informed consent to participate in the study

Trial design

1,042 participants in 3 patient groups

1

Description:

Clinical profile of patients Comorbidities and associated type of treatments will be collected.

Treatment:

Other: Clinical profile of patients

2

Description:

Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).

Treatment:

Other: Quality of Life

3

Description:

Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.

Treatment:

Other: Patient Preferences about treatment